194 related articles for article (PubMed ID: 14870961)
21. Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
Howes OD; Smith S; Aitchison KJ
Curr Med Res Opin; 2004 Oct; 20(10):1649. PubMed ID: 15462698
[No Abstract] [Full Text] [Related]
22. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
23. Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports.
Haddad PM; Hellewell JS; Wieck A
J Psychopharmacol; 2001 Dec; 15(4):293-5. PubMed ID: 11769824
[TBL] [Abstract][Full Text] [Related]
24. Hyperprolactinaemia and antipsychotic therapy in schizophrenia.
Hummer M; Huber J
Curr Med Res Opin; 2004; 20(2):189-97. PubMed ID: 15006013
[TBL] [Abstract][Full Text] [Related]
25. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study.
Abraham G; Paing WW; Kaminski J; Joseph A; Kohegyi E; Josiassen RC
Am J Psychiatry; 2003 Sep; 160(9):1618-20. PubMed ID: 12944336
[TBL] [Abstract][Full Text] [Related]
26. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Tschoner A; Engl J; Rettenbacher MA; Kaser S; Ott HW; Fleischhacker WW; Patsch JR; Ebenbichler CF
J Clin Psychiatry; 2009 Feb; 70(2):293-4. PubMed ID: 19265646
[No Abstract] [Full Text] [Related]
27. A crossover study of prolactin changes associated with risperidone and olanzapine.
Lin CY; Wu PL; Pariante CM; Su KP
J Clin Psychiatry; 2006 Sep; 67(9):1470. PubMed ID: 17017838
[No Abstract] [Full Text] [Related]
28. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.
Svestka J; Synek O; Tomanová J; Rodáková I; Cejpková A
Neuro Endocrinol Lett; 2007 Dec; 28(6):881-8. PubMed ID: 18063941
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Bushe C; Shaw M
J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
[TBL] [Abstract][Full Text] [Related]
30. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics.
Liu-Seifert H; Kinon BJ; Ahl J; Lamberson S
Ann N Y Acad Sci; 2004 Dec; 1032():297-8. PubMed ID: 15677434
[TBL] [Abstract][Full Text] [Related]
31. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.
Kishimoto T; Watanabe K; Shimada N; Makita K; Yagi G; Kashima H
J Clin Psychiatry; 2008 Mar; 69(3):385-91. PubMed ID: 18278991
[TBL] [Abstract][Full Text] [Related]
32. Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
Holzer L; Eap CB
J Clin Psychopharmacol; 2006 Apr; 26(2):167-71. PubMed ID: 16633146
[TBL] [Abstract][Full Text] [Related]
33. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.
Young RM; Lawford BR; Barnes M; Burton SC; Ritchie T; Ward WK; Noble EP
Br J Psychiatry; 2004 Aug; 185():147-51. PubMed ID: 15286066
[TBL] [Abstract][Full Text] [Related]
34. Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis.
Cookson J; Hodgson R; Wildgust HJ
J Psychopharmacol; 2012 May; 26(5 Suppl):42-51. PubMed ID: 22472310
[TBL] [Abstract][Full Text] [Related]
35. Risperidone in children with autism and serious behavioral problems.
Valiquette G
N Engl J Med; 2002 Dec; 347(23):1890-1; author reply 1890-1. PubMed ID: 12472071
[No Abstract] [Full Text] [Related]
36. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
Melkersson K; Berinder K; Hulting AL
Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
[TBL] [Abstract][Full Text] [Related]
37. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients.
Ohta C; Yasui-Furukori N; Furukori H; Tsuchimine S; Saito M; Nakagami T; Yoshizawa K; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):573-6. PubMed ID: 21216266
[TBL] [Abstract][Full Text] [Related]
38. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Lai YC; Chiou CC; Chen CH; Huang MC
J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
[No Abstract] [Full Text] [Related]
39. Second-generation antipsychotics and bone turnover in schizophrenia.
Okita K; Kanahara N; Nishimura M; Yoshida T; Yasui-Furukori N; Niitsu T; Yoshida T; Ishikawa M; Kimura H; Nomura F; Iyo M
Schizophr Res; 2014 Aug; 157(1-3):137-41. PubMed ID: 24888527
[TBL] [Abstract][Full Text] [Related]
40. [Impact of neuroleptic-induced hyperprolactinemia on sexual dysfunction in male schizophrenic patients].
Konarzewska B; Szulc A; Popławska R; Galińska B; Juchnowicz D
Psychiatr Pol; 2008; 42(1):87-95. PubMed ID: 18567406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
